Dicerna Pharmaceuticals, Inc.(NASDAQ : DRNA)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.57%||167.80||0.7%||$1089.30m|
|MRK||Merck & Co., Inc.||0.06%||81.37||0.7%||$940.61m|
|BMY||Bristol-Myers Squibb Co.||0.54%||64.95||1.0%||$741.14m|
|LLY||Eli Lilly & Co.||-2.21%||244.15||1.1%||$712.40m|
|NVO||Novo Nordisk A/S||-3.23%||96.34||0.1%||$179.86m|
|IMMX||Immix Biopharma, Inc.||0.17%||5.84||0.0%||$89.38m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.60%||122.00||0.0%||$79.45m|
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.